These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19062528)

  • 1. [Monogenic hypercholesterolemias: new genes, new drug targets].
    Mandel'shtam MIu; Vasil'ev VB
    Genetika; 2008 Oct; 44(10):1309-16. PubMed ID: 19062528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
    Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
    J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling the functional significance of PCSK9.
    Lambert G
    Curr Opin Lipidol; 2007 Jun; 18(3):304-9. PubMed ID: 17495605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9: an emerging target for treatment of hypercholesterolemia.
    Duff CJ; Hooper NM
    Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of PCSK9 function.
    Lambert G; Charlton F; Rye KA; Piper DE
    Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
    Maxwell KN; Breslow JL
    Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biology of PCSK9: its role in LDL metabolism.
    Horton JD; Cohen JC; Hobbs HH
    Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.
    Mousavi SA; Berge KE; Leren TP
    J Intern Med; 2009 Dec; 266(6):507-19. PubMed ID: 19930098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.
    Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
    Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
    Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
    Leren TP
    Clin Genet; 2004 May; 65(5):419-22. PubMed ID: 15099351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
    Mbikay M; Mayne J; Seidah NG; Chrétien M
    Med Hypotheses; 2007; 69(5):1010-7. PubMed ID: 17502126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Familial hypercholesterolemia in Tunisia].
    Jelassi A; Jguirim I; Najah M; Maatouk F; Ben Hamda K; Slimane MN
    Pathol Biol (Paris); 2009 Jul; 57(5):444-50. PubMed ID: 19041195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.